NCT03016013 2024-09-26
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
Phase 3 Completed
Clinical Trials
9 trialsNCT03589833 2022-10-25
YISTAR
Peking Union Medical College Hospital
Phase 4 Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT02882087 2019-04-03
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
RemeGen Co., Ltd.
Phase 2 Terminated
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT00361335 2014-07-29
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc.
Phase 3 Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated